Australia's most trusted
source of pharma news
Posted 15 July 2020
Roche has inked a deal worth up to US$1.7 billion with Blueprint Medicines that could bring a new cancer drug targeting a specific mutation to Australia.
The Swiss pharma giant announced the agreement this week, giving it rights to promising cancer drug pralsetinib in countries outside of the US, which include the local territory.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.